This disclosure provides methods for formulating compositions comprising oneormore peptide proteasome inhibitors and a cyclodextrin, particularly asubstitutedcyclodextrin. Such methods substantially increase the solubility and stabilityof theseproteasome inhibitors and facilitate both their manufacture andadministration.